Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

The goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in adult males.

Trial Details

NCT ID

NCT06631521

Phase

PHASE1

Sponsor

AdventHealth

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Darolutamide
Relugolix
Radical Prostatectomy

Locations (sample)

Orlando, Florida, United States|28.53834,-81.37924

Key Eligibility Criteria

Histologically or cytologically confirmed adenocarcinoma of the prostate
ECOG performance status 0-1
Ability to swallow oral medications and comply with study procedures and requirements.
Males ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →